Formulation strategies for absorption windows.
暂无分享,去创建一个
[1] G. Houin,et al. Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[2] Clive G. Wilson,et al. Gastrointestinal transit of a controlled-release pellet formulation of tiaprofenic acid and the effect of food , 1987 .
[3] Brahma N. Singh. Effects of Food on Clinical Pharmacokinetics , 1999, Clinical pharmacokinetics.
[4] I. Wilding,et al. The effect of mannitol on the oral bioavailability of cimetidine. , 1995, Journal of pharmaceutical sciences.
[5] J. Mathias,et al. Escherichia coli heat-stable toxin: its effect on motility of the small intestine. , 1982, The American journal of physiology.
[6] A. Hoffman,et al. Novel Gastroretentive Dosage Forms: Evaluation of Gastroretentivity and Its Effect on Levodopa Absorption in Humans , 2003, Pharmaceutical Research.
[7] David V. Prior,et al. Remote controlled capsules in human drug absorption (HDA) studies. , 2003, Critical reviews in therapeutic drug carrier systems.
[8] K. Matsuda,et al. Improvement in site‐specific intestinal absorption of furosemide by Eudragit L100‐55 , 2001, The Journal of pharmacy and pharmacology.
[9] Sara Eyal,et al. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[10] S. Torrado,et al. Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. , 2004, Biomaterials.
[11] M. Donnenberg,et al. Enteropathogenic Escherichia coli (EPEC) adhesion to intestinal epithelial cells: role of bundle-forming pili (BFP), EspA filaments and intimin. , 2004, Microbiology.
[12] J. Azuma,et al. Evaluation of Oral Mucoadhesive Microspheres in Man on the Basis of the Pharmacokinetics of Furosemide and Riboflavin, Compounds with Limited Gastrointestinal Absorption Sites , 1998, The Journal of pharmacy and pharmacology.
[13] O. Corrigan. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. , 1997, Advances in experimental medicine and biology.
[14] P. Bass,et al. GUANOSINE 3′,5′-CYCLIC MONOPHOSPHATE: A TAPEWORM-SECRETED SIGNAL MOLECULE COMMUNICATING WITH THE RAT HOST'S SMALL INTESTINE , 2003, The Journal of parasitology.
[15] Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers , 2003, Journal of clinical pharmacology.
[16] R. Murthy,et al. Floating dosage systems in drug delivery. , 2002, Critical reviews in therapeutic drug carrier systems.
[17] J. Schellens,et al. The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery , 2000, Investigational New Drugs.
[18] Lawrence X. Yu,et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.
[19] V. Cowles,et al. Gastric retentive dosage forms: a review. , 2003, Critical reviews in therapeutic drug carrier systems.
[20] S. Davis,et al. Chitosan microspheres prepared by spray drying. , 1999, International journal of pharmaceutics.
[21] I. Wilding,et al. The effect of ileal brake activators on the oral bioavailability of atenolol in man. , 2002, International journal of pharmaceutics.
[22] H. Onishi,et al. Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats. , 2002, Biological & pharmaceutical bulletin.
[23] H. Kanerva,et al. Gamma scintigraphic evaluation of the fate of microcrystalline chitosan granules in human stomach. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[24] S. Davis,et al. Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .
[25] I. Wilding,et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. , 2000, British journal of clinical pharmacology.
[26] A. Hoffman,et al. Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers , 2003, Journal of clinical pharmacology.
[27] I. Wilding,et al. Gastrointestinal transit of a matrix tablet formulation : comparison of canine and human data , 1993 .
[28] Henry C. Lin,et al. Slowing of intestinal transit by fat or peptide YY depends on beta-adrenergic pathway. , 2003, American journal of physiology. Gastrointestinal and liver physiology.
[29] W. Weitschies,et al. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. , 2003, Journal of pharmaceutical sciences.
[30] M. Hämäläinen,et al. Predicting the intestinal absorption potential of hits and leads. , 2004, Drug discovery today. Technologies.
[31] S. S. Davis,et al. Gastrointestinal transit of dosage forms in the pig , 2001, The Journal of pharmacy and pharmacology.
[32] K. Kolter,et al. Lauroyldextran and crosslinked galactomannan as coating materials for site-specific drug delivery to the colon. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[33] I. Wilding,et al. The role of γ-scintigraphy in oral drug delivery , 1991 .
[34] Gerrit Borchard,et al. In vitro evaluation of intestinal absorption of desmopressin using drug-delivery systems based on superporous hydrogels. , 2004, International journal of pharmaceutics.
[35] Henry C. Lin,et al. The ileal brake: A fifteen-year progress report , 1999, Current gastroenterology reports.
[36] R. Steele,et al. Intragastric Distribution of Ion‐exchange Resins: a Drug Delivery System for the Topical Treatment of the Gastric Mucosa , 1995, The Journal of pharmacy and pharmacology.
[37] G. Amidon,et al. The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine , 2003, Journal of Pharmacology and Experimental Therapeutics.
[38] A. Fasano,et al. The effect of ΔG on the transport and oral absorption of macromolecules , 2004 .
[39] P. Macheras,et al. Biopharmaceutics Of Orally Administered Drugs , 1995 .
[40] P. Watkins,et al. 6′7′‐Dihydroxybergamottin Contributes to the Grapefruit Juice Effect , 2004, Clinical pharmacology and therapeutics.
[41] G. Ponchel,et al. Gastrointestinal Transit and Mucoadhesion of Colloidal Suspensions of Lycopersicon Esculentum L. and Lotus Tetragonolobus Lectin-PLA Microsphere Conjugates in Rats , 2001, Pharmaceutical Research.
[42] Kinam Park,et al. Gastric retention properties of superporous hydrogel composites. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[43] H E Junginger,et al. Intestinal absorption of human insulin in pigs using delivery systems based on superporous hydrogel polymers. , 2002, International journal of pharmaceutics.
[44] Y. Machida,et al. Bioadhesive Characteristics of Chitosan Microspheres to the Mucosa of Rat Small Intestine , 2001, Drug development and industrial pharmacy.